Live
The US health regulator has issued four observations to Cipla across its three manufacturing facilities in Goa after the inspection.
Cipla has said in a BSE filing that “United States Food and Drug Administration (USFDA) recently concluded audit of our three manufacturing facilities in Goa and has issued four observations across these three facilities.”
It further added that these observations were primarily procedural in nature and the company has already responded to the same.
However, the company did not disclosed any details of the observations.
